Clinical trials: Hair Condition
Alopecia
A Safety and Efficacy Study of Setipiprant Tablets in Androgenetic Alopecia in Males
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).
- Trial name
- NCT02781311
- Testing
- Setipiprant, Finasteride
- Where
- 18 sites in United States
- Volunteers
- 169 people
- Sponsor
- Allergan
Androgenetic Alopecia
Modulated Light Therapy in Participants With Pattern Hair Loss
The REVIAN study is designed as a prospective, randomized, controlled, double-blind, parallel study to evaluate the efficacy and safety of the REVIAN System in male participants with androgenic alopecia.
- Trial name
- REV-01 (NCT04019795)
- Testing
- REVIAN 101, REVIAN 102, REVIAN 103
- Where
- 4 sites in Australia
- Volunteers
- 160 people
- Sponsor
- PhotonMD, Inc
Hair Thinning
Study Evaluating the Effects of Dietary Supplement on Hair Thickness and Hair Strength in Individuals With Self-Perceived Thinning Hair
The Nutra Harmony "Biotin, Collagen \& Keratin Beauty Complex" is an oral food/dietary supplement specifically designed to promote hair growth for people suffering from temporary thinning hair.
- Trial name
- NCT06605768
- Testing
- Complex with Biotin, Collagen, Keratin, Hyaluronic Acid.
- Where
- Ukraine
- Volunteers
- 80 people
- Sponsor
- Nutra Harmony LLC
Central Centrifugal Cicatricial Alopecia (CCCA)
Study to Determine Effect of Gentle Wounding to Stimulate Hair Follicle Neogenesis
The investigators have extensive evidence in mouse that wounding leads to the generation of new hair follicles in the skin. This can be an important new therapy for patients with scarring, but especially those with alopecia.
- Trial name
- NCT03491267
- Testing
- Retinoic acid, Laser
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Johns Hopkins University
Alopecia
Hair Loss Prevention Study for Pancreatic Cancer
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
- Trial name
- NCT04492800
- Testing
- Paxman Scalp Cooling Device
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- HonorHealth Research Institute
Fragile X Syndrome, Genetic Diseases
Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
The purpose of the study is to test the efficacy of a 20 week multi-modal treatment comprised of lovastatin or placebo, and the Parent-implemented Language Intervention (PILI) in children with fragile X syndrome (FXS).
- Trial name
- NCT02642653
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of California, Davis
Keloid, Alopecia Areata
Pain Outcomes Following Intralesional Corticosteroid Injections
Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics.
- Conditions
- Keloid, Alopecia Areata, Acne, Hypertrophic Scar
- Trial name
- NCT03630198
- Testing
- Corticosteroid with lidocaine, Corticosteroid with normal saline
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cicatricial Alopecia
Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia
Alopecia could be subdivided into two main groups of diseases: non-scarring alopecia, such as male pattern baldness, or alopecia areata (AA), in which hair follicles are preserved, yet quiescent, and scarring alopecia, also known…
- Trial name
- NCT05076006
- Testing
- PF-06700841
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Emma Guttman
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.
Alopecia
ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis
This Phase 2, multicenter, randomized study will evaluate the safety, tolerability and efficacy of ATI-501 for the treatment of Alopecia Areata (AA), Alopecia Universalis (AU) or Alopecia Totalis (AT) in adult subjects.
- Trial name
- NCT03594227
- Testing
- ATI-501 400mg BID (Low dose), ATI-501 600mg BID (Mid dose), ATI-501 800mg BID (High dose)
- Where
- 25 sites in United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Aclaris Therapeutics, Inc.
Hypertrichosis
Pilot Study of a Novel IPL for Removal of Unwanted Fine Body Hair
The purpose of this randomized, controlled, open-label pilot study is to evaluate the safety and efficacy of a novel intense pulsed light (IPL) device for removal of unwanted fine body hair.
- Trial name
- NCT01912950
- Testing
- Prowave LX IPL
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Cutera Inc.
Androgenetic Alopecia
A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution
Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.
- Trial name
- NCT03495817
- Testing
- ATI-50002
- Where
- 3 sites in United States
- Volunteers
- 31 people
- Sponsor
- Aclaris Therapeutics, Inc.
Male Pattern Hair Loss, Androgenetic Alopecia
Topical Bimatoprost Effect on Androgen Dependent Hair Follicles
The purpose of this study is to determine the effect of bimatoprost solution on scalp hair growth. Bimatoprost 0.03% ophthalmic solution is currently approved by the FDA for treatment of glaucoma (Lumigan™) and for thickening of…
- Trial name
- NCT02170662
- Testing
- Bimatoprost
- Volunteers
- 33 people
- Sponsor
- Duke University
Androgenetic Alopecia
A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)
The purpose of this study is to characterize the safety, tolerability, and efficacy of topical SM04554 solution (0.15% and 0.25%) applied to the scalp of male subjects with Androgenetic Alopecia (AGA).
- Trial name
- NCT02275351
- Testing
- Topical SM04554 solution, Topical vehicle solution
- Where
- 24 sites in United States
- Volunteers
- 302 people
- Sponsor
- Biosplice Therapeutics, Inc.
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Alopecia Areata
Intralesional Steroids in the Treatment of Alopecia Areata
This study aims to determine the frequency of response to treatment with 3 concentrations of IL TAC, 2.5mg/ml, 5mg/ml or 10mg/ml as well as the duration of response and incidence of side effects compared to treatment with placebo…
- Trial name
- NCT01898806
- Testing
- Intralesional Triamcinolone 2.5 mg/ml, Intralesional Triamcinolone 5 mg/ml, Intralesional Triamcinolone 10 mg/ml
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- Columbia University
Alopecia Areata
DPCP for the Treatment of Alopecia Areata
This is an open labeled study to determine the response and characteristics, safety and efficacy, of the proprietary DPCP ointment composition as a topical immunotherapeutic agent for the treatment of extensive alopecia areata.
- Trial name
- NCT03651752
- Testing
- Diphenylcyclopropenone (DPCP) Ointment
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Minnesota